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Abstract
Background: Glyoxalases (Glo1 and Glo2) are involved in the glycolytic pathway by detoxifying the reactive methylglyoxal
(MGO) into D-lactate in a two-step reaction using glutathione (GSH) as cofactor. Inhibitors of glyoxalases are considered as
anti-inflammatory and anti-carcinogenic agents. The recent finding that various polyphenols modulate Glo1 activity has
prompted us to assess curcumin’s potency as an Glo1 inhibitor.
Methodology/Principal Findings: Cultures of whole blood cells and tumor cell lines (PC-3, JIM-1, MDA-MD 231 and 1321N1)
were set up to investigate the effect of selected polyphenols, including curcumin, on the LPS-induced cytokine production
(cytometric bead-based array), cell proliferation (WST-1 assay), cytosolic Glo1 and Glo2 enzymatic activity, apoptosis/necrosis
(annexin V-FITC/propidium iodide staining;flow cytometric analysis)as wellas GSH and ATP content. Results of enzymekinetics
revealed that curcumin, compared to the polyphenols quercetin, myricetin, kaempferol, luteolin and rutin, elicited a stronger
competitive inhibitory effect on Glo1 (Ki=5.161.4 mM). Applying a whole blood assay, IC50 values of pro-inflammatory cytokine
release (TNF-a, IL-6, IL-8, IL-1b) were found to be positively correlated with the Ki-values of the aforementioned polyphenols.
Moreover, whereas curcumin was found to hamper the growth of breast cancer (JIMT-1, MDA-MB-231), prostate cancer PC-3
and brain astrocytoma 1321N1 cells, no effect on growth or vitality of human primary hepatocytes was elucidated. Curcumin
decreased D-lactate release by tumor cells, another clue for inhibition of intracellular Glo1.
Conclusions/Significance: The results described herein provide new insights into curcumin’s biological activities as they
indicatethatinhibitionofGlo1bycurcuminmayresultinnon-tolerablelevelsofMGOandGSH,which,inturn,modulatevarious
metabolic cellular pathways including depletion of cellular ATP and GSH content. This may account for curcumin’s potency as
an anti-inflammatory and anti-tumor agent. The findings support the use of curcumin as a potential therapeutic agent.
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Introduction
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-
3,5-dione) is a polyphenol derived from the plant Curcuma longa.
The medical use of this plant has its roots in the Indian Ayurveda
medicine for over 6000 years. Extensive research over the last
decades has indicated that curcumin exhibits anti-inflammatory,
anti-oxidant, anti-viral and anti-infectious activities [1,2]. Further-
more, in various animal models, curcumin was found to suppress
symptoms associated with type II diabetes [3] rheumatoid arthritis
[4], Alzheimer disease [5], promoted wound healing [6] and was
protective in an animal model of sepsis [7]. These effects seem to be
linked to the anti-inflammatory effect of curcumin that, in turn, may
be attributed to its ability to inhibit cyclooxygenase-2, lipoxygenase
and inducible nitric oxide synthase (iNOS) [8]. Recently, the
involvement of the peroxisome proliferator-activated receptor-
gamma has been shown [9].
Curcumin such as other polyphenols is as strong anti-oxidant
[10]. It significantly decreases lipid peroxidation, regulates anti-
oxidant enzymes and scavenges hyperglycemia-induced reactive
oxygen species (ROS) [11]. Oxidative stress and inflammation are
closely associated with tumor growth [12]. Therefore, it is not
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different stages of the tumor development [13]. The low incidence
of colon cancer among Indians has been attributed to the use of
curcumin in cooking in addition to other dietary compounds [14].
However, a possible dominance of certain genetic prerequisites in
these populations can not be excluded.
Anti-proliferative effects of curcumin are suggested to be
mediated by induction of apoptosis in a mitochondria-dependent
manner via caspase-3 activation [15]. In addition, curcumin could
affect cellular proliferation by modulating of various cell signaling
pathways including NF-kB, growth factor receptor kinases and
mitogen-activated protein kinases [16]. Although, the multiple
biological functions of curcumin have been described, the prime
driving mechanism underlying its action remains unknown [17].
In the present study we provide evidence that the diverse actions
of curcumin may be mediated by inhibiting cellular glyoxalases.
Glyoxalases are involved in the detoxification of the reactive
MGO formed para-metabolically and para-enzymatically from
triosephosphates when glucose is degraded. Glo1 catalyzes the
conversion of cytotoxic MGO to nontoxic hemithioacetal using
GSH as cofactor. This enzyme is ubiquitously expressed in all
mammalian cells and is suggested to be involved in cellular aging
and cell death [18].
Inhibitors of Glo1 have long been sought as possible anticancer
agents. High affinity inhibitors were prepared as GSH analogues
such as S-p-bromobenzylglutathione and were shown to display
anti-proliferative action [19]. However, the ubiquity of GSH and
its involvement in vital cellular reactions may limit the use of
native GSH analogues as inhibitors. We found that curcumin acts
as a strong inhibitor of Glo1, causes depletion of cellular ATP and
GSH and thus has a potential impact at cellular metabolism
predominantly in cells whose energy gain relies on the glycolytic
pathway. Inhibition of Glo1 seems to be an important route by
which this dietary agent may exert its diverse biological effects.
Results
Curcumin inhibits glyoxalase 1 with high affinity
Recently, some polyphenols such as quercetin, luteolin, myricetin,
and kaempferol have been shown to inhibit Glo1 [20–22]. To see
whether curcumin inhibits the enzyme similar to these dietary
compounds, we analyzed the enzyme activity in the presence of
increasing amounts of inhibitors at different concentrations of the
substrates MGO and GSH. The Dixon plot analysis revealed that
enzyme inhibition by curcumin was competitive with Ki=5.16
1.4 mM (Fig. 1). Compared to curcumin, inhibition by other
polyphenols turned out to be significantly lower and yielded Ki-
values of 2364.5 mM, 1362.9 mM, 2163.8 mM, 3566.3 mM,
140615 mM for quercetin, myricetin, kaempferol, luteolin and rutin,
respectively.
Curcumin exerts an anti-inflammatory effect on LPS-
stimulated blood cells
Polyphenols are known for their anti-inflammatory effects on
immune cells. To compare the effect of curcumin with other
polyphenols displaying flavonoid structure, we applied whole
blood assays whereby monocytes were stimulated with LPS at
37uC/5% CO2 and incubated for 6 h (Fig. 2). LPS-stimulated
blood cells release pro-inflammatory cytokines such as TNF-a, IL-
6, IL-1b and IL-8. Upon addition of curcumin and other selected
flavonoids at increasing concentrations to the cultured cells, we
observed a strong suppression of the pro-inflammatory cytokine
release as exemplified by IL-1b (Fig. 2). The results of the current
study rank curcumin at the top of the investigated polyphenols
with respect to inhibition of pro-inflammatory cytokine produc-
tion. IC50 values of 7.9 mM, 20 mM, 34.6 mM and 68 mM have
been estimated for curcumin, quercetin, kaempferol, and luteolin,
respectively. None of these compounds was found to induce IL-1b
release in the absence of LPS. Moreover, at concentrations above
200 mM, these compounds induced red blood cell lysis. A strong
positive correlation was found between the anti-inflammatory
activity (IC50) and the in vitro Ki-values of curcumin, quercetin,
kaempferol and luteolin (Spearman’s R=0.90) indicating that
Glo1 inhibition may be a possible mechanism to explain the anti-
inflammatory effects of these polyphenols.
Curcumin inhibits growth of cancer cells via targeting
glyoxalase 1
It is known that inhibitors of Glo1, structurally related to GSH,
have anti-proliferative properties [19]. To study the action of
curcumin on cell growth, we incubated different tumor cells with
increasing concentrations of curcumin for 24 h and measured
changes in cell proliferation applying WST-1 assay (Fig. 3).
Curcumin effectively inhibited the growth of different cancer cell
lines derived from prostate cancer (PC-3), breast cancer (MDA-
MB-231, JIMT-1), and brain astrocytoma (1321N1). Curcumin-
treated cells manifested a dose-dependent reduction in cell
proliferation (Fig. 3A). Obviously, the cellular activity of curcumin
is biphasic. At low concentrations, it is stimulatory rather than
inhibitory, especially in the range between 1 mM and 10 mM. This
effect was observed predominantly in prostate and breast cancer
cells and was absent in astrocytoma cells. However, strong anti-
proliferative effects were observed at concentrations above 50 mM
for all cancer cells tested. Not only did curcumin inhibit cell
growth as seen for 1321N1, MDA-MB-231 and JIMT-1 cells, but
it also exerted even a toxic effect at 100 mM on PC-3 cells. In this
case, the normal cellular morphology got lost indicating necrotic
cell death. Comparable to curcumin, both of quercetin and
myricetin, which also inhibited Glo1 activity, were less anti-
proliferative to 1321N1 cells. This indicates that the growth
suppressing effect of the studied polyphenols may be related to the
Ki-values for Glo1 inhibition as shown in figure 1.
Following 6-h incubation of 1321N1 cells with curcumin (50 mM),
cell shrinking and chromatin condensation accompanied by a
massive loss of cytoplasm was observed (data not shown). This may
be indicative to metabolically depressed tumor cells. Surprisingly, cell
membranes integrity at this stage was apparently not altered as
indicated by L-LDH release that was not significantly increased
(F i g .4 A ),a sw e lla sb yt h ep e r ce n t a g eo fv i t a lc e ll sm e a s u r e db yt r y p a n
blue exclusion that was only slightly diminished (89.5%62.5% vs.
95.6%62.5%) (Fig.4B).However,longer incubation(24-h)increased
the LDH release and significantly reduced the number of vital cells to
60%66.1% relative to the control.
To proof that inhibition of the Glo1activity accounts for cellular
effects, we exposed JIMT-1 breast carcinoma cells to curcumin for
24 h. After cell harvesting and solubilisation, we found that
specific Glo1 activity in treated cells was lower than in non-treated
cells and decreased dose-dependently (Fig. 5A). As a control, we
measured the LDH activity, another cytosolic enzyme, which we
found to be increased at higher curcumin concentrations. This
indicates the very selective effect of curcumin at the para-glycolytic
enzyme Glo1. Again, a small augmentation of Glo1 activity was
observed at 10 mM curcumin which may reflect the findings
shown in figure 3. Estimating the protein level, Western blot
analysis revealed no alteration of Glo1 content (Fig. 5B). This
substantiates the assumption that curcumin acts as an enzyme
inhibitor rather than through modulating the expression or
degradation of Glo1. We found similar effects with other tumor
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D-lactate in the medium of cultured 1321N1 cells incubated with
increasing concentrations of curcumin for 24 h. D-lactate is
produced in the MGO pathway as the end-product of the Glo2
enzymatic reaction. Inhibition of glyoxalases is known to result in a
decrease in D-lactate release. Our results demonstrated that D-
lactate decreased from 34.666 mM in the control cells to
2261.9 mMa t2 0mM curcumin.(Fig. 5C). This indicates that
cytosolic Glo1 is inhibited by curcumin and thereby may result in
accumulation of MGO.
Because MGO rapidly forms hemithioacetal with GSH,
elevated MGO will, in turn, deplete cellular GSH levels especially
at low expression level of Glo2. Therefore, we investigated
whether MGO may, at least partially, account for the anti-
Figure 1. Inhibition of glyoxalase 1 activity by polyphenolic compounds. Purified Glo1 (70 mU) was incubated with increasing
concentrations of different polyphenols at three substrate concentrations; and enzyme activity was recorded (n=3). The inhibitor concentration was
plotted vs. the reciprocal of enzyme activity (1/v) in Dixon plots.
doi:10.1371/journal.pone.0003508.g001
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1cells with increasing concentrations of the reactive aldehyde
(Fig. 6). The results disclose the anti-proliferative properties of
MGO. Because MGO exerts its effect predominantly intracellular,
we expected that the concentration of MGO that reaches the cell
is much lower than what was added to the medium. This means
that MGO rapidly reacts with amino and sulfhydryl groups of
proteins abundantly present in the culture medium (10% fetal calf
serum). In this regard, it has been reported that the intracellular
concentrations of MGO in normal growing cells can be elevated
up to 300 mM [23].
As shown in figure 7, curcumin-treated 1321N1 and JIMT-1
cells revealed decreased GSH levels. GSH was diminished by
approximately 20% in cells treated with 50 mM curcumin, a
concentration which yields approximately 30% inhibition of cell
proliferation as presented in figure 3. This may be linked to the
increasingly formed hemithioacetal that might trap GSH. This
trapping can be magnified in case of a low Glo2 activity, an
enzyme that hydrolyzes the S-lactoylglutathione, the end product
of Glo1, to release D-lactate and to regenerate GSH. Therefore,
we measured the Glo2 activity in cytosolic cell extracts (Table 1).
The results demonstrated between 10- and 70-fold decrease in
specific activity of Glo2 compared to Glo1 in different tumor cell
lines. Thus, the low expression of Glo2 is suggested to impair the
regeneration of GSH. Obviously, this could add additional effects
to the GSH depletion.
Curcumin leads to metabolic depletion of ATP
It has been shown that MGO affects energy metabolism [24]. If
curcumin-induced Glo1 inhibition leads to accumulation of
MGO, both of curcumin and MGO are expected to have similar
effects at metabolic activity of tumor cells. Therefore, we analyzed
the ATP-content of 1321N1 and JIMT-1 cells treated with various
concentrations of curcumin and MGO. As shown in figure 8,
curcumin decreased cellular ATP in a concentration-dependent
manner and MGO disclosed comparable effects.
Curcumin is cytotoxic to cancer cells but not to primary
human hepatocytes
Increased MGO [25], depletion of GSH [26] and ATP [27] are
known to initiate apoptotic cell death. We questioned whether
curcumin inhibits tumor cell growth by induction of apoptosis.
Figure 2. Effect of polyphenols on IL-1b release from LPS-stimulated blood cells. Heparinized whole blood was stimulated by LPS in the
absence or presence of polyphenols at increasing concentrations and incubated for 6 h at 37uC with 5% CO2. (A) Released IL-1b as measured in cell
supernatants. Samples without additives but LPS were set at 100%. (B) The calculated LD50 values of the respective polyphenols. Data represent
mean6S.D. of independent experiments (n=6).
doi:10.1371/journal.pone.0003508.g002
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37uC/5% CO2 in the presence of increasing concentrations of curcumin or the flavonoids quercetin or myricetin. Following 24-h incubation, cell
proliferation was evaluated using the WST-1 assay.
doi:10.1371/journal.pone.0003508.g003
Figure 4. Release of L-lactate dehydrogenase (L-LDH) and vitality of 1321N1 cells upon incubation with 50 mM curcumin. Tumor cells
were cultured and treated as mentioned in Fig. 3. (A) LDH activity was measured in cell supernatants. (B) Cell vitality as assayed by the trypan blue
exclusion test. Data represent the mean6S.D. of independent experiments (n=6).
doi:10.1371/journal.pone.0003508.g004
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curcumin and analyzed for annexin V-5-fluorescein isothiocyanate
(FITC)/propidium iodide (PI) binding (Fig. 9A and 9B).
The results show that curcumin induced apoptosis in 1321N1
cells. Curcumin at a concentration of 10 mM was found to induce
early apoptosis of 11.0% of cells characterized by the intactness of
membrane, affinity towards annexin V-FITC and devoid of PI
staining. At higher concentration of curcumin (50 mM), the
number of late apoptotic/necrotic cells increased up to 98.2%.
This accords the results shown in figure 4.
Primary human hepatocytes, on the other hand, were not
affected by curcumin as shown by the lack of any change in the cell
vitality in the presence of increasing concentrations of curcumin
(Fig. 9C).
Discussion
Anti-proliferative and anti-inflammatory activity of
curcumin
Curcumin possesses a wide range of pharmacological properties
including anti-inflammatory, anti-infectious, and anti-carcinogenic
activities [28]. A number of different targets have been proposed
to mediate these different effects which include transcription
factors, enzymes, cytokines and cell receptors [1,13]. In the present
work we have added a further target of curcumin, the Glo1.
Notwithstanding the numerous studies, Glo1 has never been
reported or suggested to be a binding target of curcumin.
Inhibitors of glyoxalases have long been sought as possible anti-
cancer drugs. In this sense, analogues of GSH such as S-p-
bromobenzylglutathione have been prepared and used to inhibit
the growth of cancer cells [19]. However, the use of high affinity
glutathione-based inhibitors has many drawbacks due to interfer-
ence with many other GSH-dependent enzymes in vivo.
Recently, natural inhibitors of Glo1 have been selected from
flavonoids, polyphenolic compounds found in many plants [22].
This prompted us to test whether the polyphenol curcumin exerts
similar properties. We found that curcumin showed even a stronger
inhibitory effect on Glo1 than the flavonoids quercetin, myricetin,
kaempferol,luteolinand rutin.Its inhibitoryactivityexpressed bythe
Ki value was in the range of that of S-p-bromobenzylglutathione
known to be the strongest inhibitor of Glo1 [22].
Growth inhibition curve of cancer cells treated with curcumin
showed a biphasic feature. At low concentrations, curcumin was
found to stimulate cell proliferation rather than being inhibitory.
The reason for this biphasic action is currently not known, but it
may be related to the polyvalent activity of curcumin, so that
different cellular pathways are activated in a concentration-
dependent manner. Such a distinct dose-related behavior was
already observed in case of stimulated mouse macrophages treated
with curcumin [29]. At high concentrations, curcumin was found
to act probably via inactivation of NF-kB compared to modulation
of the heme oxygenase expression at low concentrations.
Similarly, curcumin was found to act as an anti-oxidant at low
doses, whereas at higher doses the pro-oxidant properties prevailed,
a virtue that may be of high importance in cell apoptosis and
treatment of cancer cells [30]. In addition, the down-regulation of
pro-inflammatorycytokinesismostlikelymediatedbyinactivationof
the transcription factor NF-kB signaling system although the precise
mechanism is not known [31]. No chemical modification of the NF-
kB signaling pathway by curcumin was found and the site of
intervention was supposed to precede the phosphorylation steps.
We could imply that curcumin had a strong impact at the highly
proliferative and invasive tumor cells such as 1321N1, PC-3 and
MDA-MB-231. Currently, there are no drugs for successful
treatment of human astrocytoma and glioma tumors. This might
be of interest in the light of the finding that curcumin is capable to
cross the blood-brain-barrier [5].
This would increase the list of therapeutic application of
curcumin comprehensively described earlier [32].
The striking differences found between the IC50 values for
cytokine suppression compared to values for the anti-proliferative
activity of curcumin let us assume that this polyphenol possesses an
anti-inflammatory potency at low concentrations, whereas higher
concentrations are required to mediate an anti-proliferative effect.
Figure 5. Cytosolic activity and protein content of glyoxalase 1
upon treatment of JIMT-1 cells with curcumin. (A) JIMT-1 cells
were treated with curcumin at 37uC and 5% CO2 for 24 h. Cells were
harvested and the specific activity of Glo1 and LDH was determined in
the cytosolic extract. (B) Semi-quantitative analysis of protein content as
performed by Western blot using specific antibodies against b-actin and
Glo1. The blot was developed by chemoluminescense detection. (C) D-
lactate release as determined in supernatants of astrocytoma 1321N1
cells following 24-h incubation with curcumin. Data represent the
mean6S.D. of independent experiments (n=6).
doi:10.1371/journal.pone.0003508.g005
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mononuclear blood cells compared to tumor cells. Glo1 is highly
expressed in cancerous cells to compensate for the permanent
formation of MGO due to the high glycolytic rate. The specific
activity of Glo1 in mononuclear blood cells was approximately 1/10
compared to tumor cells (unpublished data). Thus, lower concen-
trations of Glo1 inhibitors are required to mediate cellular effects.
Proposed mechanism of curcumin action
The expression of glyoxalases is normally adjusted to the flux of
glucose through the glycolytic pathway. Many cancer cells gain
their energy mainly by oxidation of glucose to lactate showing a
high aerobic glycolysis [33]. To compensate the low ATP gain via
glycolysis, these cells must increase their glycolytic flux several
folds. Consequently, this increases the level of MGO to toxic
concentrations for the respective cells [24]. Therefore, most cancer
cells show increased expression of Glo1 [34].
The key events in cellular metabolism upon glyoxalase
inhibition are the elevated levels of MGO and depletion of
GSH. Both alterations will have profound effects on regulatory
processes and on cellular bioenergetics. There are reports showing
that MGO is toxic to cells by depleting ATP, modulation of
mitochondrial membrane potential, induction of apoptosis and
ROS-production [24,35]. MGO is capable to modify the function
of very distinct proteins, e.g. activation of transcription factors in
yeast [36], distinct covalent modifications of proteins like Hsp27
[37] or modulation of enzyme activity of GAPDH [38]. Results of
a recent paper supported our hypothesis in the broadest sense that
MGO, by reacting with Cys 38 of NF-kB p65, inhibits its binding
to DNA [39]. These data coincide with the observed effects of
curcumin at the mitochondrial membrane permeability and
inhibition of ATP synthesis [40], as well as suppressed activation
of NF-kB. However, the specific target within this signaling
pathway has not been identified yet [41]. NF-kB activation
Figure 6. Effect of methylglyoxal on proliferation of astrocytoma and breast cancer cells. Astrocytoma 1321N1 (5000 cells/well) and
breast cancer cells JIMT-1 were seeded (start) and cultured in the absence or presence of increasing concentrations of MGO for 24 h. Cell vitality was
recorded by WST-1 assay. Data represent the mean6S.D. of independent experiments (n=12).
doi:10.1371/journal.pone.0003508.g006
Figure 7. Effect of curcumin on glutathione (GSH) level of 1321 N1 and JIMT-1 cells. Astrocytoma 1321N1 (A) and JIMT-1 (B) cells were
cultured for 24 h at 37uC and 5% CO2 in the absence or presence of curcumin. Cells were harvested and GSH concentration was determined in the
cytosolic extract. Data represent the mean6S.D. of independent experiments (n=6).
doi:10.1371/journal.pone.0003508.g007
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induces inflammation [42]. Therefore, we suggest that the anti-
proliferative and ant-inflammatory effect of curcumin might be at
least partially mediated by inhibition of Glo1.
As far as GSH is concerned, increased levels of MGO may
cause cellular depletion of GSH due to hemithioacetal formation.
Low levels of GSH have been found to decrease resistance of
cancer cells to chemotherapeutic drugs [43], boost cell apoptosis
[44] and mediate ROS-induced mitochondrial damage [45].
Without knowing the precise site of action, curcumin treatment
was associated with decreased intracellular GSH which may
account for its pro-apoptotic effects [46] but is inconsistent with
the observed anti-oxidant properties of curcumin [47]. Recently, it
has been convincingly shown that a number of flavonoids can
induce GSH depletion in human tumor cells. However, the
mechanism how polyphenols can drive GSH depletion has not
been published yet [48]. The observed decrease of intracellular
GSH and ATP content of tumor cells may cooperate in mediating
toxic effects on cells at higher concentrations of curcumin. As far
as ATP depletion is concerned, it can currently not be dissipated
whether this may be caused by direct inhibition of glycolysis or by
toxic effects of MGO or curcumin on mitochondria.
Inhibition of Glo1 by compounds unrelated to GSH has been
described recently for flavonoids and indomethacin [22,49].
Selected from flavonoids, Takasawa et al. [22] proposed that
compounds possessing a plane configuration of a ketone and a
hydroxy group arranged in a distance of 2.8 A may mimic the
enediolate intermediate that yields along the reaction pathway of
Table 1. Specific activity of Glo1
1, Glo2 and GSH
2 content in various tumor cells.
Cell type Glo1 (U/mg protein) Glo2 (U/mg protein) GSH (mmol/mg protein)
Brain astrocytoma 1321N1 0.960.08 0.0260.004 0.0860.005
Breast cancer MDA-MD-231 0.460.04 0.0360.008 0.0360.003
Prostate cancer PC-3 1.460.09 0.0260.009 0.0560.009
Breast cancer JIMT-1 1.1760.02 0.0260.01 0.0660.01
Cytosolic extracts were prepared from cultured tumor cells and specific activity of enzymes and GSH was determined as described in Materials and Methods. The values
represent means6S.D. determined in triplicates (n=6).
1glyoxalase 1 & glyoxalase 2.
2glutathione.
doi:10.1371/journal.pone.0003508.t001
Figure 8. Effect of curcumin and methylglyoxal (MGO) at the ATP level in tumor cells. Astrocytoma 1321N1 cells (A) and JIMT-1cells (B)
were seeded (5000 cells/well) and cultured in the presence of curcumin (0–100 mM) or MGO (0–1000 mM) for 6 h. Cellular ATP content was
determined using the CellTiter-GloH Luminescent Cell Viability Assay. Data represent the mean6S.D. of independent experiments (n=12).
doi:10.1371/journal.pone.0003508.g008
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elements (keto-enol forms), it is conceivable that this pharmaco-
phore directly interacts with the active site of Glo1. Curcumin may
exist at equilibrium between the diketo and keto-enol forms; the
latter is strongly favored by intramolecular H-bonding. In this line,
it has been suggested that these structural elements appear to be
important for its anti-tumor activity [50]. Recently, we could
evidenced that compounds harboring ‘‘dicarbonyl’’ groups such as
ethyl pyruvate possess an anti-inflammatory potency and suppress
the expression of immune receptors on human macrophages via
targeting human Glo1 [51].
It has been reported that curcumin can directly react with SH
groups of glutathione and cysteine residues in proteins [52].
However, it is not conceivable that this may affect the cellular
GSH content because the intracellular concentration of curcumin
is expected to be too low compared to that of GSH.
Figure 9. Effect of curcumin on apoptosis/necrosis of tumor and normal cells. Apoptosis/necrosis was evaluated using annexin V-5-
fluorescein isothiocyanate (FITC)/propidium iodine (PI) staining followed by flow cytometric analysis. (A) Representative plots of showing annexin V-
FITC/PI staining of Astrocytoma 1321N1 cells cultured in the presence of curcumin. The proportion of dead cells (a: annexin V-FITC
2/PI
+), late
apoptotic/necrotic cells (b: annexin V-FITC
+/PI
+), non-apoptotic cells (c: annexin V-FITC
2/PI
2) and early apoptotic cells (d: annexin V-FITC
+/PI
2). (B)
Results of 3 independent experiments. (C) Vitality response of primary human hepatocytes to 24-h incubation with curcumin as assessed by WST-1
test. Data represent the mean6S.D. of three independent experiments.
doi:10.1371/journal.pone.0003508.g009
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bridges energy metabolism, especially glycolysis, to inhibition of
cell growth. That may be the reason why Glo1 is critical for cell
survival [53] and that Glo1 inhibitors may constitute potent
chemotherapeutic agents [34]. In addition, it may also explain
why curcumin is also active against inflammation, bacteria and
protozoa [11,54,55]. Inflammation process is always accompanied
by activation of glycolytic pathway in specific cells such as
monocytes/macrophages or lymphocytes. Furthermore, bacteria
as well as protozoa such as malaria parasites and trypanosome are
mainly glucose-consuming organisms. As these organisms do not
possess NF-kB pathway, one of the predicted targets of curcumin,
it is likely that curcumin may act through glyoxalase inhibition, in
addition to other proposed mechanisms [56].
In conclusion, the present study may designate the natural
product curcumin as a strong competitive inhibitor of Glo1. This
will increase our understanding of the anti-inflammatory and anti-
proliferative effects of curcumin and may provide new insights into
how curcumin exerts its anti-carcinogenic effect.
Materials and Methods
Materials
Curcumin, myricetin, luteolin, kaempferol and quercetin were
obtained from Roth (Karlsruhe, Germany). 5,59-Dithio-bis(2-
nitrobenzoic acid) (DTNB), methylglyoxal, lipopolysaccharide (E.
coli Serotype O111:B4), S-lactoylglutathione, propidium iodide,
trypan blue, L-lactate, D-lactate, D-lactate dehydrogenase (D-
LDH) (Lactobacillus leichmannii) and L-lactate dehydrogenase (L-
LDH) (bovine heart), EDTA, glycerol, Triton X-100, 1,4-
dithiothreitol (DTT), phenylmethanesulfonyl fluoride (PMSF),
William Medium E and protease inhibitor cocktail were purchased
from Sigma-Aldrich (Taufkirchen, Germany). RPMI 1640 medi-
um was purchased from Biochrom (Berlin, Germany). Cell
proliferation reagent WST-1 was obtained from Roche (Man-
nheim, Germany). BD
TM CBA Human Inflammation Kit was
purchased from BD Biosciences (Heidelberg, Germany). Annexin
V-FITC was obtained from Immunotools (Marseille, France).
Dulbecco’s modified Eagle Medium (DMEM), RPMI Medium
and fetal calf serum (FCS) were obtained from Invitrogen
(Karlsruhe, Germany). Anti-human Glo1 monoclonal antibodies
were purchased from BioMac (Leipzig, Germany). Tumor cell
lines used are prostate cancer PC-3 (CRL-1435; ATCC), brain
astrocytoma 1321N1 cells (86030102; ECACC) and human breast
JIMT-1 (ACC 589; DSMZ) and MDA-MB-231 (HTB-26; ATCC)
cancer cells.
Application of curcumin
A stock solution of curcumin (50 mM) was prepared in DMSO.
Just before adding to cultured cells, curcumin was diluted in
culture medium as required keeping the final DMSO concentra-
tion at 1%.
Whole blood assay
Whole blood assay was performed as previously described [57].
Accordingly, LPS (10 ng/ml), test substances and 200 ml hepa-
rinized human blood of healthy donors, obtained from the blood
Figure 10. Keto-Enol Tautomeric forms of curcumin and transition-state of glutathione (GSH) and methylglyoxal (MGO). (A) (1E,6E)-
1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione. (B) (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-triene-3-one.
(C) Transition-state compound of reaction between GSH and MGO.
doi:10.1371/journal.pone.0003508.g010
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free medium (RPMI-SF, 1 ml final volume) in 24-well culture
plates for 6 h at 37uC with 5% CO2. Samples were removed,
centrifuged at 20006g for 10 min and supernatants were stored at
220uC until assaying for inflammatory cytokines.
Cytokine analysis using cytometric bead array
Assessment of cytokine levels in supernatants of human blood
cell cultures was accomplished using Cytometric Bead Array
(CBA
TM, BD Biosciences, San Jose, U.S.A). The procedure was
carried out according to the manufacturer’s instruction. Fluores-
cence measurement and analysis were performed using a
FACSCalibur and the CellQuest software (BD Biosciences).
Mammalian cell culture
Tumor cells were cultured in RPMI medium containing 10%
fetal calf serum (RPMI-FCS) (PC-3, JIMT-1, MDA-MD 231) or in
DMEM-FCS (astrocytoma 1321N1 cells) containing penicillin/
streptomycin (100 U penicillin/ml; 100 mg streptomycin/ml) at
37uC/5% CO2. Cytosolic protein extracts of tumor cells were
prepared using extraction buffer composed of 25 mM Tris, 2 mM
EDTA, 10% Glycerol, 1% Triton 6100, 2 mM DTT, 1mM
PMSF, pH. 7.0 containing 0.3% protease inhibitor cocktail.
Protein content was determined according to Bradford [58].
Specific activity of enzymes analyzed in cell extracts was expressed
as U/mg protein.
Primary human hepatocytes were isolated and cultivated in
serum-free William Medium E [59]. Tissue samples from human
liver resection were obtained from patients undergoing partial
hepatectomy for metastatic liver tumor of colorectal cancer.
Experimental procedures were performed according to the
guidelines of the charitable state controlled foundation (Human
Tissue and Cell Research), with the informed patient’s consent
[60] approved by the local ethical committee.
Purification of glyoxalases
Glo1 was purified from human erythrocytes as described earlier
[61]. Briefly, erythrocytes were treated with butanol/chloroform
to denature hemoglobin followed by acetone and ammonium
sulphate fractionation. Repeated affinity chromatography on S-
hexylglutathione-Agarose followed by gel permeation chromatog-
raphy yielded the enzyme; purity.90%.
Glyoxalase activity measurement
The determination of Glo1 (E.C.4.4.1.5) activity has been
described previously [61]. To evaluate the effect of curcumin and
other polyphenols on Glo1 enzymatic activity, 2 mM GSH and
2 mM MGO were pre-incubated for 4 min, and then mixed
with increasing concentrations of test substances together with
70 mU of the enzyme. The inhibition constant, Ki value of the
inhibitors was evaluated by Dixon plot showing the reciprocal of
enzyme velocity against the inhibitor concentration at variable
concentrations of the substrate. Human Glo2 (E.C.3.1.2.6) was
measured using the substrate S-lactoylglutathione as described
earlier [62].
LDH activity measurement
LDH activity was spectrophotometrically assayed in the
cytosolic extract or in the of cell cultures by adding aliquots to
1 ml reaction buffer (50 mM Na2HPO4, pH 7.0, 0.15 mM
NADH, and 0.3 mM pyruvate). Enzyme activity was recorded
at 340 nm. It was ascertained that the enzyme activity was not
affected by curcumin.
Measurement of L-lactate and D-lactate
The determination of D-lactate and L-lactate in supernatants of
astrocytoma 1321N1 cells was performed by an enzymatic method
based on the oxidation of L-lactate and D-lactate to pyruvate by
NAD in the presence of L-LDH or D-LDH[63].
Apoptosis/necrosis measurement
Astrocytoma 1321N1 cells were treated with increasing amounts
of curcumin for 24 h, washed with PBS and after trypsination,
apoptosis/necrosis was evaluated using annexin V-FITC/propi-
dium iodine (PI) staining as previously described [64]. Samples
were analyzed by flow cytometry using a FACSCalibur and the
CellQuest software (BD Biosciences, San Jose, USA). Laser
excitation wavelength was set at 488 nm. The green signal from
annexin V-FITC was measured at 525 nm and the red signal from
PI was measured at 620 nm. Annexin V
2/PI
2 cells are viable;
annexin V
+/PI
2 cells are in early apoptosis, whereas annexin V
+/
PI
+ cells are necrotic or in late apoptosis are
Glutathione determination
GSH was determined using DTNBmethod [65].Briefly,cytosolic
extract of tumor cells were precipitated by 5% sulfosalicylic acid
neutralization, aliquotswere mixed with DTNB and absorbancewas
read at 412 nm against a standard solution of GSH.
Cell proliferation/vitality assays
Cell proliferation/vitality of tumor cells (96-well plates;
5000 cells/well) and primary human hepatocytes (24-well plates;
0.25610
6 cells/well) was assayed using the WST-1 assay accord-
ing to manufacturer’s instructions. Trypan blue exclusion was
performed by staining cells with 0.4% aqueous trypan blue
solution according to the manufacturer’s instructions.
ATP measurement
Cell ATP content was determined by means of the CellTiter-
GloH Luminescent Cell Viability Assay according to the
manufacturer’s instructions (Promega, Madison, USA). Briefly,
tumor cells were cultured in 96-well plates (5000 cells/well) in the
absence or presence of curcumin or MGO, respectively. After 6-h
incubation, cells were mixed with test reagents and luminescence
was read according to the manufacturer’s instructions. A standard
curve was prepared from ATP (1 mM to 10 nM) in medium.
Western blot analysis
An amount of 20 mgt o4 0mg of cytosolic extract was loaded to
SDS-pore gradient gels (4 to 20%) and run under reducing
conditions. Proteins were blotted to cellulose nitrate membranes
(Whatman Schleicher & Schuell, Dassel, Germany) and Glo1 was
detected by anti-Glo1 monoclonal antibodies (1 mg/ml) (BioMac,
Leipzig, Germany) in combination with goat anti-mouse Ig-HRP
(1:1000) (Dako, Hamburg, Germany). For comparison, b-actin
was analyzed using rabbit anti-b-actin Ig (1:2000) (Acris,
Hiddenhausen, Germany) in conjunction with HRP-labeled goat
anti-rabbit Ig (Dianova, Hamburg, Germany). Band visualization
was performed by chemiluminescence detection (Boehringer,
Mannheim, Germany).
Statistical analysis
Kinetic data (Fig. 1) were analyzed with the GraphPad Prism
3.03 (GraphPad Software Inc. San Dieago, CA) using the
Marquardt-Levenberg method with simple weighting. A good-
ness-of-fit criterion (Akaike’s information criterion, AIC) was used
for falsification of incompatible inhibition models. It turned out
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The quality of the fit was characterized by 95% confidence
intervals of the estimated parameters and the total residual error.
Spearman’s rank correlation test was applied to evaluate the
correlation between the IC50 values of pro-inflammatory cytokine
release and the Ki-values of various polyphenols. Data were
presented as means6S.D. of at least three independent experi-
ments. The enzyme inhibition by polyphenols (Ki-values) are
considered significant at p=0.1 (Wilcoxon’s rank-sum test). In all
other tests, significance has been considered at values of p,0.05.
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